Company news
Prothena Corporation plc news in 2021
Prothena Corporation plc's news releases, calls and decks from 2021, newest first.
Prothena Reports Third Quarter 2021 Financial Results and Business Highlights
November 3, 2021
Prothena to Report Third Quarter 2021 Financial Results on November 4th
October 27, 2021
Prothena Announces Executive Appointments
September 30, 2021
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 2, 2021
Prothena Reports Second Quarter 2021 Financial Results and Business Highlights
August 4, 2021
Prothena to Report Second Quarter 2021 Financial Results on August 5th
July 28, 2021
Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021
July 25, 2021
Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
July 11, 2021
Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
June 23, 2021
Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors
May 19, 2021
Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update
May 10, 2021
Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease
May 9, 2021
Prothena to Report First Quarter 2021 Financial Results on May 11th
May 3, 2021
Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
April 17, 2021
Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021
April 14, 2021
Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer
April 4, 2021
Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares
March 23, 2021
Prothena Announces Proposed Offering of Ordinary Shares
March 22, 2021
Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
February 23, 2021
Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
February 10, 2021
Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th
February 3, 2021
Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
January 31, 2021